Clinical trial • Phase III • Immunology|Dermatology

JNJ-77242113 for Moderate to severe plaque psoriasis

Phase III trial of JNJ-77242113 for Moderate to severe plaque psoriasis.

Overview

Trial Therapeutic Area
Immunology|Dermatology
Trial Disease
Moderate to severe plaque psoriasis
Trial Stage
Phase III
Drug Modality
Peptide/protein/enzyme|Monoclonal antibody
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
15-01-2025
First CTIS Authorization Date
06-05-2025

Trial design

Randomised, active comparator: ustekinumab (stelara) — stelara 90 mg solution for injection in pre-filled syringe and stelara 45 mg solution for injection (doses 90 mg and 45 mg are specified); placebo controls: film-coated tablet without jnj-77242113 and solution for injection without ustekinumab (45 mg) and solution for injection in pre-filled syringe without ustekinumab (90) — schedule/frequency not specified in the record. Phase III trial in Austria, Germany, Poland and others.

Randomised
Yes
Comparator
Active comparator: Ustekinumab (STELARA) — STELARA 90 mg solution for injection in pre-filled syringe and STELARA 45 mg solution for injection (doses 90 mg and 45 mg are specified); Placebo controls: Film-Coated Tablet without JNJ-77242113 and Solution for injection without Ustekinumab (45 mg) and Solution for injection in pre-filled syringe without Ustekinumab (90) — schedule/frequency not specified in the record.
Target Sample Size
273

Eligibility

Recruits 273 paediatric patients.

Vulnerable Population
Adolescents are included (minimum age ≥12 years) and the trial has selected vulnerable population status. Assent and parental/guardian consent procedures are provided (documents include Adolescent Assent, Child Assent, Parent/Guardian ICF, Optional Sample Assent/ICF, Optional Sub-study ICF). Materials and ICF/assent templates are available in multiple country/language versions as provided (examples: German, English, Portuguese, Polish, Hungarian, Spanish, French, Dutch, Danish). Parental/legal guardian consent is required for minors with adolescent/child assent as applicable.

Inclusion criteria

  • {"criterion_text":"- 1.≥12 years of age at the screening visit."}
  • {"criterion_text":"- 2. Diagnosis of moderate to severe plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention."}
  • {"criterion_text":"- 3. Total BSA ≥10% at screening and baseline."}
  • {"criterion_text":"- 4. Total PASI ≥12 at screening and baseline."}
  • {"criterion_text":"- 5. Total IGA ≥3 at screening and baseline."}

Exclusion criteria

  • {"criterion_text":"- 1.Nonplaque form of psoriasis"}
  • {"criterion_text":"- 2.Current drug-induced psoriasis"}
  • {"criterion_text":"- 3.A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances."}
  • {"criterion_text":"- 4.Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients"}
  • {"criterion_text":"- 5.Major surgical procedure (eg, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16.","definition_or_measurement_approach":"IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16."}
  • {"endpoint_text":"- PASI 90 at Week 16.","definition_or_measurement_approach":""}

Recruitment

Digital Remote Recruitment
Yes
Planned Sample Size
273
Recruitment Window Months
31
Consent Approach
Informed consent is obtained from adult participants and from parents/legal guardians for minors; adolescents/children provide assent. Multiple ICF and assent templates are provided (Adolescent Assent, Child Assent, Parent/Guardian ICF, Optional sample/optional sub-study ICF, Withdrawal forms, Pregnant partner ICF). Documents are provided in multiple country/language versions (examples: German, English, Portuguese, Polish, Hungarian, Spanish, French, Dutch, Danish) as indicated in the submitted materials.

Methods

  • Social media and web posts / digital adverts (e.g., 'Adolescent Social Med Web AD', 'Social Media and Web Post') — country-specific versions indicated (DE, PL, PT, BE, DK, ES). Target audience: adolescents and caregivers.
  • Patient flyers and study information brochures (e.g., 'Patient Flyer', 'Study Information Brochure') distributed via clinical sites and local channels — country-specific versions provided.
  • Caregiver and adolescent brochures ('Caregiver and Adolescent Brochure') targeted to caregivers and adolescent participants.
  • Dear Parent letters and emails (e.g., 'Dear Parent Letter', 'Dear Parent Email') targeted to parents/guardians of adolescent potential participants.
  • Subject Wallet Card provided to participants ('Subject Wallet Card').

Geography

Total Number Of Sites
69
Total Number Of Participants
434

Austria

Earliest CTIS Part Ii Submission Date
25-04-2025
Latest Decision Or Authorization Date
12-05-2025
Processing Time Days
17
Number Of Sites
5
Number Of Participants
20

Sites

Site Name
Klinik Hietzing
Department Name
Dermatologische Abteilung
Principal Investigator Name
Christian Posch
Principal Investigator Email
christian.posch@gesundheitsverbund.at
Contact Person Name
Christian Posch
Site Name
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH
Department Name
Abteilung für Dermatologie und Venerologie
Principal Investigator Name
Nina Haering
Principal Investigator Email
nina.haering@lkhf.at
Contact Person Name
Nina Haering
Contact Person Email
nina.haering@lkhf.at
Site Name
Noe LGA Gesundheit Region Mitte GmbH
Department Name
Klinische Abteilung für Haut- und Geschlechtskrankheiten
Principal Investigator Name
Knut Prillinger
Principal Investigator Email
knut.prillinger@stpoelten.lknoe.at
Contact Person Name
Knut Prillinger
Site Name
Johannes Kepler University Linz
Department Name
Universitätsklinik für Dermatologie und Venerologie
Principal Investigator Name
Wolfram Hoetzenecker
Principal Investigator Email
Wolfram.Hoetzenecker@kepleruniklinikum.at
Contact Person Name
Wolfram Hoetzenecker
Site Name
Medical University Of Vienna
Department Name
Universitätsklinik für Dermatologie
Principal Investigator Name
Jonak Constanze
Principal Investigator Email
constanze.jonak@meduniwien.ac.at
Contact Person Name
Jonak Constanze

Germany

Earliest CTIS Part Ii Submission Date
23-04-2025
Latest Decision Or Authorization Date
06-05-2025
Processing Time Days
13
Number Of Sites
13
Number Of Participants
102

Sites

Site Name
Universitaet Muenster
Department Name
Universitätsklinikum Münster, Klinik für Hautkrankheiten
Principal Investigator Name
Nina Magnolo
Principal Investigator Email
nina.magnolo@ukmuenster.de
Contact Person Name
Nina Magnolo
Contact Person Email
nina.magnolo@ukmuenster.de
Site Name
Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR
Principal Investigator Name
Michael Sebastian
Principal Investigator Email
dr.sebastian@hautarztpraxis-mahlow.de
Contact Person Name
Michael Sebastian
Site Name
Hautarztpraxis Dr. Hoffmann
Principal Investigator Name
Matthias Hoffmann
Principal Investigator Email
drho@hautarzt-dr-hoffmann.de
Contact Person Name
Matthias Hoffmann
Contact Person Email
drho@hautarzt-dr-hoffmann.de
Site Name
Thermalsole und Schwefelbad Bentheim GmbH
Department Name
Fachklinik Bad Bentheim Abteilung für Dermatologie
Principal Investigator Name
Athanasios Tsianakas
Principal Investigator Email
a.tsianakas@fk-bentheim.de
Contact Person Name
Athanasios Tsianakas
Contact Person Email
a.tsianakas@fk-bentheim.de
Site Name
Studienzentrum Dr. Schwarz
Principal Investigator Name
Beate Schwarz
Principal Investigator Email
beate@hautarzt-langenau.de
Contact Person Name
Beate Schwarz
Contact Person Email
beate@hautarzt-langenau.de
Site Name
Universitaetsklinikum Augsburg
Department Name
Klinik fuer Dermatologie und Allergologie
Principal Investigator Name
Julia Welzel
Principal Investigator Email
julia.welzel@uk-augsburg.de
Contact Person Name
Julia Welzel
Contact Person Email
julia.welzel@uk-augsburg.de
Site Name
Studienzentrum an der Hase Weyergraf/Frick/Heiber GbR
Principal Investigator Name
Ansgar Weyergraf
Principal Investigator Email
aweyergraf_dzosn@web.de
Contact Person Name
Ansgar Weyergraf
Contact Person Email
aweyergraf_dzosn@web.de
Site Name
ISA Interdisciplinary Study Association GmbH
Principal Investigator Name
Margrit Simon
Principal Investigator Email
msimon@isa-research.de
Contact Person Name
Margrit Simon
Contact Person Email
msimon@isa-research.de
Site Name
Universitaetsklinikum Bonn AöR
Department Name
Klinik für Dermatologie und Allergologie, Studienzentrum Dermatologie
Principal Investigator Name
Dagmar Wilsmann-Theis
Principal Investigator Email
dagmar.wilsmann-theis@ukbonn.de
Contact Person Name
Dagmar Wilsmann-Theis
Site Name
Universitaetsklinikum Schleswig-Holstein AöR
Department Name
Klinik für Dermatologie, Allergologie und Venerologie (Hautklinik)
Principal Investigator Name
Sascha Gerdes
Principal Investigator Email
sgerdes@dermatology.uni-kiel.de
Contact Person Name
Sascha Gerdes
Site Name
Rosenpark Research GmbH
Principal Investigator Name
Oliver Weirich
Principal Investigator Email
oliver.weirich@rosenparkresearch.de
Contact Person Name
Oliver Weirich
Site Name
BAG Dres. med. Quist PartG
Principal Investigator Name
Sven Roy Quist
Principal Investigator Email
s.quist@dermatologie-quist.de
Contact Person Name
Sven Roy Quist
Contact Person Email
s.quist@dermatologie-quist.de
Site Name
Derma-Study-Center Friedrichshafen GmbH
Principal Investigator Name
Peter Radny
Principal Investigator Email
radny@dsc-fn.de
Contact Person Name
Peter Radny
Contact Person Email
radny@dsc-fn.de

Poland

Earliest CTIS Part Ii Submission Date
28-04-2025
Latest Decision Or Authorization Date
13-05-2025
Processing Time Days
15
Number Of Sites
13
Number Of Participants
150

Sites

Site Name
Klinika Ambroziak Sp. z o.o.
Department Name
Klinika Ambroziak Dermatologia
Principal Investigator Name
Bartlomiej Kwiek
Principal Investigator Email
michal@klinikaambroziak.pl
Contact Person Name
Bartlomiej Kwiek
Contact Person Email
michal@klinikaambroziak.pl
Site Name
Care Clinic Sp. z o.o.
Principal Investigator Name
Dominika Wcislo-Dziadecka
Principal Investigator Email
poczta@careclinic.katowice.pl
Contact Person Name
Dominika Wcislo-Dziadecka
Contact Person Email
poczta@careclinic.katowice.pl
Site Name
Solumed Sp. z o.o. sp.k.
Principal Investigator Name
Kinga Adamska
Principal Investigator Email
office@solumed.pl
Contact Person Name
Kinga Adamska
Contact Person Email
office@solumed.pl
Site Name
Centrum Medyczne Oporow
Principal Investigator Name
Joanna Maj
Principal Investigator Email
badania@cmoporow.com
Contact Person Name
Joanna Maj
Contact Person Email
badania@cmoporow.com
Site Name
Velocity Skierniewice Sp. z o.o.
Principal Investigator Name
Witold Urban
Principal Investigator Email
feasibility@VelocityClinical.com
Contact Person Name
Witold Urban
Site Name
Specderm Poznanska Sp. j.
Principal Investigator Name
Maria Poznanska
Principal Investigator Email
badania@specderm.pl
Contact Person Name
Maria Poznanska
Contact Person Email
badania@specderm.pl
Site Name
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.
Principal Investigator Name
Jan Brzezicki
Principal Investigator Email
kontakt@ckb.elblag.pl
Contact Person Name
Jan Brzezicki
Contact Person Email
kontakt@ckb.elblag.pl
Site Name
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
Principal Investigator Name
Agata Maciejewska-Radomska
Principal Investigator Email
tomaszpesta@etykaosrodek.pl
Contact Person Name
Agata Maciejewska-Radomska
Contact Person Email
tomaszpesta@etykaosrodek.pl
Site Name
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy s.c.​
Principal Investigator Name
Pawel Brzewski
Principal Investigator Email
info@dermatolog-brzewski.com
Contact Person Name
Pawel Brzewski
Contact Person Email
info@dermatolog-brzewski.com
Site Name
Dermed Centrum Medyczne Sp. z o.o.
Principal Investigator Name
Andrzej Kaszuba
Principal Investigator Email
rejestracja.a2@dermed.com.pl
Contact Person Name
Andrzej Kaszuba
Contact Person Email
rejestracja.a2@dermed.com.pl
Site Name
Carpe Diem Centrum Medycyny Estetycznej
Principal Investigator Name
Weronika Molga
Principal Investigator Email
carpediem@carpediempl.eu
Contact Person Name
Weronika Molga
Contact Person Email
carpediem@carpediempl.eu
Site Name
Wromedica I Bielicka A Strzalkowska s.c.
Principal Investigator Name
Wojciech Baran
Principal Investigator Email
biuro@wromedica.pl
Contact Person Name
Wojciech Baran
Contact Person Email
biuro@wromedica.pl
Site Name
NZOZ ZDROWIE OSTEO-MEDIC
Principal Investigator Name
Malgorzata Janczylo-Jankowska
Principal Investigator Email
sekretariat@osteo-medic.pl
Contact Person Name
Malgorzata Janczylo-Jankowska
Contact Person Email
sekretariat@osteo-medic.pl

Hungary

Earliest CTIS Part Ii Submission Date
24-03-2025
Latest Decision Or Authorization Date
07-05-2025
Processing Time Days
44
Number Of Sites
10
Number Of Participants
75

Sites

Site Name
Medmare Bt.
Principal Investigator Name
Levente Kővágó
Principal Investigator Email
drkovago@gmail.com
Contact Person Name
Levente Kővágó
Contact Person Email
drkovago@gmail.com
Site Name
Derma-B Kft.
Principal Investigator Name
Emese Clemens-Herédi
Principal Investigator Email
emeseheredi@gmail.com
Contact Person Name
Emese Clemens-Herédi
Contact Person Email
emeseheredi@gmail.com
Site Name
Bacs-Kiskun Varmegyei Oktatokorhaz
Department Name
Borgyogyaszati Osztaly
Principal Investigator Name
Ivan Orojan
Principal Investigator Email
orojani@kmk.hu
Contact Person Name
Ivan Orojan
Contact Person Email
orojani@kmk.hu
Site Name
Vasarhelyi Sarkanyfu Kft.
Principal Investigator Name
Eva Balazs
Principal Investigator Email
jimbies@gmail.hu
Contact Person Name
Eva Balazs
Contact Person Email
jimbies@gmail.hu
Site Name
Obudai Egeszseguegyi Centrum Kft.
Principal Investigator Name
Judit Noll
Principal Investigator Email
nolljudit@gmail.com
Contact Person Name
Judit Noll
Contact Person Email
nolljudit@gmail.com
Site Name
Gyoengyosi Bugat Pal Koerhaz
Department Name
Borgyogyaszati szakrendeles
Principal Investigator Name
Andrea Mihalik
Principal Investigator Email
dr.mihalika@gmail.com
Contact Person Name
Andrea Mihalik
Contact Person Email
dr.mihalika@gmail.com
Site Name
Allergo-Derm Bakos Kft.
Principal Investigator Name
Noémi Bakos
Principal Investigator Email
bakosnoemidr@gmail.com
Contact Person Name
Noémi Bakos
Contact Person Email
bakosnoemidr@gmail.com
Site Name
University Of Debrecen
Department Name
Bőrgyógyászat Klinika
Principal Investigator Name
Andrea Szegedi
Principal Investigator Email
aszegedi@med.unideb.hu
Contact Person Name
Andrea Szegedi
Contact Person Email
aszegedi@med.unideb.hu
Site Name
Uno Medical Trials Kft.
Principal Investigator Name
Eva Apostol
Principal Investigator Email
broadway21@freemail.hu
Contact Person Name
Eva Apostol
Contact Person Email
broadway21@freemail.hu
Site Name
Somogy Varmegyei Kaposi Mor Oktato Korhaz
Department Name
Borgyogyaszat
Principal Investigator Name
Beata Fabos
Principal Investigator Email
fabosbeata@gmail.com
Contact Person Name
Beata Fabos
Contact Person Email
fabosbeata@gmail.com

Portugal

Earliest CTIS Part Ii Submission Date
28-04-2025
Latest Decision Or Authorization Date
19-05-2025
Processing Time Days
21
Number Of Sites
5
Number Of Participants
15

Sites

Site Name
Hospital Cuf Descobertas S.A.
Department Name
Dermatology
Principal Investigator Name
Pedro Mendes Bastos
Principal Investigator Email
pedro.mm.bastos@cuf.pt
Contact Person Name
Pedro Mendes Bastos
Contact Person Email
pedro.mm.bastos@cuf.pt
Site Name
Unidade Local De Saude De Santo Antonio E.P.E.
Department Name
Dermatology
Principal Investigator Name
Tiago Torres
Contact Person Name
Tiago Torres
Site Name
Unidade Local De Saude Da Regiao De Leiria E.P.E.
Department Name
Dermatology
Principal Investigator Name
Martinha Henrique
Principal Investigator Email
martinha.henrique@ulsrl.min-saude.pt
Contact Person Name
Martinha Henrique
Site Name
Unidade Local De Saude De Sao Jose E.P.E.
Department Name
Dermatology
Principal Investigator Name
Miguel Coelho
Principal Investigator Email
miguel.coelho@ulssjose.min-saude.pt
Contact Person Name
Miguel Coelho
Site Name
Unidade Local De Saude Do Alto Ave E.P.E.
Department Name
Dermatology
Principal Investigator Name
Fernando Mota
Principal Investigator Email
fernandojrmota@gmail.com
Contact Person Name
Fernando Mota
Contact Person Email
fernandojrmota@gmail.com

Belgium

Earliest CTIS Part Ii Submission Date
03-04-2025
Latest Decision Or Authorization Date
08-05-2025
Processing Time Days
35
Number Of Sites
2
Number Of Participants
20

Sites

Site Name
Universitair Ziekenhuis Gent
Department Name
Dermatology
Principal Investigator Name
Jo Lambert
Principal Investigator Email
dermatologie@uzgent.be
Contact Person Name
Jo Lambert
Contact Person Email
dermatologie@uzgent.be
Site Name
UZ Leuven
Department Name
Dermatology
Principal Investigator Name
Tom Hillary
Principal Investigator Email
tom.hillary@uzleuven.be
Contact Person Name
Tom Hillary
Contact Person Email
tom.hillary@uzleuven.be

Spain

Earliest CTIS Part Ii Submission Date
28-03-2025
Latest Decision Or Authorization Date
07-05-2025
Processing Time Days
40
Number Of Sites
16
Number Of Participants
37

Sites

Site Name
Grupo Dermatologico Y Estetico Pedro Jaen S.A.
Department Name
Dermatology
Principal Investigator Name
Alvaro Gonzalez Cantero
Principal Investigator Email
alvarogc261893@hotmail.com
Contact Person Name
Alvaro Gonzalez Cantero
Contact Person Email
alvarogc261893@hotmail.com
Site Name
Complexo Hospitalario Universitario De Santiago
Department Name
Dermatology
Principal Investigator Name
Maria Isabel Rodriguez Blanco
Principal Investigator Email
sabeblanco@gmail.com
Contact Person Name
Maria Isabel Rodriguez Blanco
Contact Person Email
sabeblanco@gmail.com
Site Name
Hospital General Universitario Dr. Balmis
Department Name
Dermatology
Principal Investigator Name
Isabel Belinchon Romero
Principal Investigator Email
belinchon_isa@gva.es
Contact Person Name
Isabel Belinchon Romero
Contact Person Email
belinchon_isa@gva.es
Site Name
Hospital Clinic De Barcelona
Department Name
Dermatology
Principal Investigator Name
Josep Riera Monroig
Principal Investigator Email
jriera@clinic.cat
Contact Person Name
Josep Riera Monroig
Contact Person Email
jriera@clinic.cat
Site Name
Hospital Universitario Miguel Servet
Department Name
Dermatology
Principal Investigator Name
Tamara Gracia Cazana
Principal Investigator Email
tgraciac@salud.aragon.es
Contact Person Name
Tamara Gracia Cazana
Contact Person Email
tgraciac@salud.aragon.es
Site Name
Hospital Universitario Virgen De Valme
Department Name
Dermatology
Principal Investigator Name
Amelia Perez Gil
Principal Investigator Email
amalia.perezgil@gmail.com
Contact Person Name
Amelia Perez Gil
Contact Person Email
amalia.perezgil@gmail.com
Site Name
Hospital Marina Baixa De La Vila Joiosa
Department Name
Dermatology
Principal Investigator Name
Francisco Javier Mataix Diaz
Principal Investigator Email
mataixdiaz@hotmail.com
Contact Person Name
Francisco Javier Mataix Diaz
Contact Person Email
mataixdiaz@hotmail.com
Site Name
Hospital Universitario Clinico San Cecilio
Department Name
Dermatology
Principal Investigator Name
Jose Carlos Ruiz Carrascosa
Principal Investigator Email
ruizcarrascosa@movistar.es
Contact Person Name
Jose Carlos Ruiz Carrascosa
Contact Person Email
ruizcarrascosa@movistar.es
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Dermatology
Principal Investigator Name
Lara Ferrandiz Pulido
Principal Investigator Email
lferrandiz@e-derma.org
Contact Person Name
Lara Ferrandiz Pulido
Contact Person Email
lferrandiz@e-derma.org
Site Name
Hospital De Manises
Department Name
Dermatology
Principal Investigator Name
Antonio Martorell Calatayud
Principal Investigator Email
antmarto@hotmail.com
Contact Person Name
Antonio Martorell Calatayud
Contact Person Email
antmarto@hotmail.com
Site Name
Hospital Universitario De La Princesa
Department Name
Dermatology
Principal Investigator Name
Mar Llamas Velasco
Principal Investigator Email
mar.llamasvelasco@gmail.com
Contact Person Name
Mar Llamas Velasco
Contact Person Email
mar.llamasvelasco@gmail.com
Site Name
Hospital Universitario 12 De Octubre
Department Name
Dermatology
Principal Investigator Name
Raquel Rivera Diaz
Principal Investigator Email
raquel.rivera@salud.madrid.org
Contact Person Name
Raquel Rivera Diaz
Contact Person Email
raquel.rivera@salud.madrid.org
Site Name
Icr Medical S.L.
Department Name
Dermatology
Principal Investigator Name
Alvaro Gonzalez Cantero
Principal Investigator Email
alvarogc261893@hotmail.com
Contact Person Name
Alvaro Gonzalez Cantero
Contact Person Email
alvarogc261893@hotmail.com
Site Name
Hospital Clinico Universitario Lozano Blesa
Department Name
Dermatology
Principal Investigator Name
Mariano Ara Martin
Principal Investigator Email
mariano_ara@yahoo.es
Contact Person Name
Mariano Ara Martin
Contact Person Email
mariano_ara@yahoo.es
Site Name
Hospital Universitario De Cruces
Department Name
Dermatology
Principal Investigator Name
Olatz Lasa Elgezua
Principal Investigator Email
olatz.lasaelgezua@osakidetza.eus
Contact Person Name
Olatz Lasa Elgezua
Site Name
Hospital Universitario Y Politecnico La Fe
Department Name
Dermatology
Principal Investigator Name
Rafael Botella Estrada
Principal Investigator Email
rbotellaes@gmail.com
Contact Person Name
Rafael Botella Estrada
Contact Person Email
rbotellaes@gmail.com

Denmark

Earliest CTIS Part Ii Submission Date
30-04-2025
Latest Decision Or Authorization Date
06-05-2025
Processing Time Days
6
Number Of Sites
5
Number Of Participants
15

Sites

Site Name
Odense University Hospital
Department Name
Department of Dermatology
Principal Investigator Name
Kawa Khaled Ajgeiy
Principal Investigator Email
kawa.ajgeiy@rsyd.dk
Contact Person Name
Kawa Khaled Ajgeiy
Contact Person Email
kawa.ajgeiy@rsyd.dk
Site Name
Gentofte Hospital
Department Name
Department of Dermatology and Allergy
Principal Investigator Name
Lone Skov
Principal Investigator Email
lone.skov.02@regionh.dk
Contact Person Name
Lone Skov
Contact Person Email
lone.skov.02@regionh.dk
Site Name
Region Hovedstaden
Department Name
Dep. Of Dermato-Venereology and wound healing
Principal Investigator Name
Simon Francis Thomsen
Principal Investigator Email
simon.francis.thomsen.02@regionh.dk
Contact Person Name
Simon Francis Thomsen
Site Name
Aalborg University Hospital
Department Name
Afdeling for Hud- og Kønssygdomme
Principal Investigator Name
Kasper Fjellhauden Hjuler
Principal Investigator Email
kf.hjuler@rn.dk
Contact Person Name
Kasper Fjellhauden Hjuler
Contact Person Email
kf.hjuler@rn.dk
Site Name
Aarhus University Hospital
Department Name
Hud og kønssygdomme
Principal Investigator Name
Christian Vestergaard
Principal Investigator Email
chrivest@rm.dk
Contact Person Name
Christian Vestergaard
Contact Person Email
chrivest@rm.dk

Sponsor

Primary sponsor

Full Name
Janssen Cilag International
Organisation Type
Pharmaceutical company
Country Of Registered Address
Belgium

Contract research organisations

Name
4g Clinical LLC
Responsibilities
Sponsor third party (role code 3 indicated)
Name
Eresearchtechnology Inc.
Responsibilities
Sponsor third party (role codes 7,8 indicated)

Third parties

  • {"country":"United States","full_name":"4g Clinical LLC","duties_or_roles":"sponsorDuties codes: 3 (role code provided in submission)","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"sponsorDuties codes: 7, 8 (roles indicated by codes in submission)","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Labcorp Central Laboratory Services LP","duties_or_roles":"kit production; sponsorDuties codes: 15 (kit production), 4, 5, 6","organisation_type":"Pharmaceutical company"}

Investigational products

Investigational Product Name
JNJ-77242113
Active Substance
JNJ-77242113
Modality
Peptide/protein/enzyme
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
Investigational (no marketing authorisation listed in record)
Investigational Product Name
STELARA 45 mg solution for injection
Active Substance
USTEKINUMAB
Modality
Monoclonal antibody
Routes Of Administration
SUBCUTANEOUS USE
Route
Subcutaneous
Authorisation Status
Authorised (marketing authorisation: EU/1/08/494/001)
Starting Dose
45 mg
Dose Levels
45 mg
Investigational Product Name
STELARA 90 mg solution for injection in pre-filled syringe
Active Substance
USTEKINUMAB
Modality
Monoclonal antibody
Routes Of Administration
SUBCUTANEOUS USE
Route
Subcutaneous
Authorisation Status
Authorised (marketing authorisation: EU/1/08/494/004)
Starting Dose
90 mg
Dose Levels
90 mg
Investigational Product Name
Film-Coated Tablet without JNJ-77242113 (placebo)
Modality
Other
Authorisation Status
Not applicable (placebo)
Investigational Product Name
Solution for injection without Ustekinumab 45 (placebo injection)
Modality
Other
Authorisation Status
Not applicable (placebo)
Investigational Product Name
Solution for injection in pre-filled syringe without Ustekinumab 90 (placebo injection)
Modality
Other
Authorisation Status
Not applicable (placebo)

Related trials

Other published trials that may interest you.